Reports
Status | Drug name | NICE TAs | Comments |
---|---|---|---|
Balsalazide | Consultant initiation - only when other agents have been ineffective |
||
Bambuterol tablets | Specialist initiation for severe brittle asthma / CF |
||
Betamethasone 0.1% eye drops | |||
Betamethasone 0.1%, neomycin 0.5% eye drops | Short term use only |
||
Betaxolol eye drops | Specialist ophthalmologist recommendation |
||
Bicalutamide tablets | |||
Bimatoprost eye drops | |||
Brinzolamide 1% and Brimonidine 0.2% eye drops (Simbrinza) | Specialist ophthalmologist recommendation |
||
Brinzolamide eye drops | Specialist ophthalmologist recommendation |
||
Brivaracetam (Briviact®) | Initiation by Tertiary Epilepsy Specialist only. For adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age, with severe refractory epilepsy warranting tertiary specialist input for patients who have tried three or more AEDs. The patient has used levetiracetam and has documentation of intolerance and patient is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam. ESCA required. |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.